inotuzumab
pfizer,ucb
['leusm', 'inotuzumab']
congress #eha22 | reported results of phase ii study of inotuzumab ozogamicin (ino) in adult pts with mrd+ b-all. n=20, median follow-up=15 months. 24 months os=61%, overall mrd- rate=60% with &gt;80% response attained after 1 cycle of ino #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm